↓ Skip to main content

Clinical trial simulation methods for estimating the impact of DPP-4 inhibitors on cardiovascular disease

Overview of attention for article published in ClinicoEconomics and Outcomes Research: CEOR, June 2015
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (61st percentile)
  • Good Attention Score compared to outputs of the same age and source (66th percentile)

Mentioned by

twitter
4 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
5 Dimensions

Readers on

mendeley
18 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Clinical trial simulation methods for estimating the impact of DPP-4 inhibitors on cardiovascular disease
Published in
ClinicoEconomics and Outcomes Research: CEOR, June 2015
DOI 10.2147/ceor.s75935
Pubmed ID
Authors

Siew Hwa Ong, Matthias Blüher, Andy Schuetz

Abstract

Dipeptidyl peptidase-4 (DPP-4) inhibitors are a class of oral antidiabetic agents for the treatment of type 2 diabetes mellitus, which lower blood glucose without causing severe hypoglycemia. However, the first cardiovascular (CV) safety trials have only recently reported their results, and our understanding of these therapies remains incomplete. Using clinical trial simulations, we estimated the effectiveness of DPP-4 inhibitors in preventing major adverse cardiovascular events (MACE) in a population like that enrolled in the SAVOR-TIMI (the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus - Thrombolysis in Myocardial Infarction) 53 trial. We used the Archimedes Model to simulate a clinical trial of individuals (N=11,000) with diagnosed type 2 diabetes and elevated CV risk, based on established disease or multiple risk factors. The DPP-4 class was modeled with a meta-analysis of HbA1c and weight change, pooling results from published trials of alogliptin, linagliptin, saxagliptin, sitagliptin, and vildagliptin. The study treatments were added-on to standard care, and outcomes were tracked for 20 years. The DPP-4 class was associated with an HbA1c drop of 0.66% (0.71%, 0.62%) and a weight drop of 0.14 (-0.07, 0.36) kg. These biomarker improvements produced a relative risk (RR) for MACE at 5 years of 0.977 (0.968, 0.986). The number needed to treat to prevent one occurrence of MACE at 5 years was 327 (233, 550) in the elevated CV risk population. Consistent with recent trial publications, our analysis indicates that DPP-4 inhibitors do not increase the risk of MACE relative to the standard of care. This study provides insights about the long-term benefits of DPP-4 inhibitors and supports the interpretation of the published CV safety trial results.

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 18 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 18 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 5 28%
Researcher 4 22%
Student > Bachelor 2 11%
Unspecified 2 11%
Student > Ph. D. Student 1 6%
Other 4 22%
Readers by discipline Count As %
Medicine and Dentistry 8 44%
Unspecified 4 22%
Agricultural and Biological Sciences 2 11%
Nursing and Health Professions 1 6%
Immunology and Microbiology 1 6%
Other 2 11%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 June 2015.
All research outputs
#2,053,138
of 5,222,019 outputs
Outputs from ClinicoEconomics and Outcomes Research: CEOR
#54
of 191 outputs
Outputs of similar age
#66,591
of 176,409 outputs
Outputs of similar age from ClinicoEconomics and Outcomes Research: CEOR
#6
of 18 outputs
Altmetric has tracked 5,222,019 research outputs across all sources so far. This one has received more attention than most of these and is in the 60th percentile.
So far Altmetric has tracked 191 research outputs from this source. They receive a mean Attention Score of 2.6. This one has gotten more attention than average, scoring higher than 71% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 176,409 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 61% of its contemporaries.
We're also able to compare this research output to 18 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.